KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company’s initial focus is on the facial aesthetics market. The Company’s product candidate, ATX-101, is an injectable drug in late-stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. The Company’s ATX-101 treatment contours the area under the chin by destroying fat cells while leaving surrounding tissue largely unaffected. The Company’s Phase II and Phase III studies have demonstrated that ATX-101, when injected subcutaneously into the target fat deposit, reduces the localized fat deposit while leaving the surrounding tissue largely unaffected. It is an attractive non-surgical solution for the reduction of submental fat.